HOME >> BIOLOGY >> NEWS
JCI Table of Contents, 15 August 2003

Anti-asthma medications: too much of a good thing?

In an unusual paradox, asthmatics that are chronically treated with bronchodilating beta-agonist medications such as albuterol, ventolin, and salbutamol may ultimately develop increased sensitivity to airway constriction and experience exacerbation of their condition. A new study by Stephen Liggett and colleagues at the University of Cincinnati in the August 15 issue of the Journal of Clinical Investigation describes a responsible mechanism for this adverse reaction and reveals a potential new therapeutic target in the treatment of asthma.

Inhaled selective beta-agonists are the most widely used treatment for the acute relief of asthma symptoms. Administered to asthmatic patients via an inhaler, nebulizer, in tablet or liquid form, or injection, they cause airway relaxation and reduced airway responsiveness to nonspecific contractile stimuli. This is achieved by drug binding to the beta2-adrenergic receptor (beta2AR). Despite the ability of these agents to immediately reverse airway obstruction, there has been ongoing concern that the use of these drugs may be associated with harmful outcomes. Some, but not all, studies have revealed that regular scheduled use (e.g., multiple times daily, every day) of inhaled beta-agonists has resulted in a loss of control over the condition, which can manifest as longer asthmatic attacks and and post-treatment airway hyperresponsiveness.

To date, the evidence has suggested that a desensitization of the beta2AR is responsible. Liggett and colleagues suggest an alternative explanation. The authors demonstrate that persistent high-level activation of the beta2AR leads to increased expression of phospholipase C-beta (PLC-beta) in airway smooth muscle, inducing a crosstalk between beta2AR signaling pathways that ultimately results in airway hyperresponsiveness.

In their accompanying commentary, Stephanie Shore and Jeffrey Drazen from the Harva
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
15-Aug-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is ... is the most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made ... three-year revenue growth of 71 percent. , The Inc. 5000 list represents a ...
(Date:8/21/2020)... ... August 19, 2020 , ... The 19th Annual Bio-IT ... data science, informatics and IT leaders goes VIRTUAL and announces its updated event ... change, Bio-IT takes the leadership role of keeping our life science community connected ...
(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, a fast-growing provider ... Eric Chen and Jessica Wong have joined the company’s leadership team as Vice ... Eric Chen heads development efforts for Alucio’s flagship product, Beacon, an innovative cloud-based ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... (PRWEB) , ... August 29, 2020 , ... ... new Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will ... quality standards and advanced technology. , “This facility will improve the flexibility ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), ... The network is a consortium of academic research centers in the United States ...
(Date:8/7/2020)... (PRWEB) , ... August 06, 2020 , ... ... DNA vaccine industries, announces it has closed on the purchase of greenfield for ... in Conroe, TX and includes over 21 acres in the initial acquisition, with ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International ... only $3950. With 50 million stem cells total, patients may choose which extremities they ... works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue ...
Breaking Biology Technology:
Cached News: